{"meta":{"query_hash":"24ee0efe4bbb","filters":{"venue":"International Journal of Hematologic Oncology"},"cohort_total":3,"direct_labels_cover":0,"predictions_cover":3,"exported":3,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/24ee0efe4bbb","api":"https://metacan.xera.ac/api/v1/cohort?venue=International+Journal+of+Hematologic+Oncology"},"results":[{"id":"W2077076503","doi":"10.2217/ijh.14.35","title":"Ruxolitinib for the Treatment of Disease-Related Splenomegaly or Symptoms in Adult Patients with Myelofibrosis","year":2014,"lang":"en","type":"article","venue":"International Journal of Hematologic Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Alberta","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Constitutional symptoms; Myeloproliferative neoplasm; Anemia; Natural history; Disease; Internal medicine; Pediatrics; Intensive care medicine; Bone marrow","score_opus":0.01445894224092989,"score_gpt":0.3111262826682992,"score_spread":0.2966673404273693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077076503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86239725,0.11371626,0.0014695248,0.0055247443,0.00034113004,0.00017171762,0.00037913118,0.00014226878,0.01585803],"genre_scores_gemma":[0.9857453,0.010624871,0.0010580333,0.0011347425,0.0002683136,0.000041741623,0.0002522937,0.000003940488,0.0008706972],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9999399,0.000019700105,0.000010104341,0.0000051999696,0.0000093301705,0.000015767886],"domain_scores_gemma":[0.9998692,0.000034173085,0.000033908833,0.0000037344973,0.0000124306125,0.0000466182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024789662,0.00014310573,0.00035062054,0.00017520413,0.00019829553,0.0001883282,0.000106312524,0.00028631336,0.00076391303],"category_scores_gemma":[0.0003282167,0.00004720348,0.0001688204,0.00013258474,0.00009730979,0.00014308363,0.00011817281,0.00049467536,0.00021855545],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009850192,0.0011470241,0.15299945,0.0014225688,0.0003423302,0.033251557,0.00042917478,0.0012916906,0.02749965,0.0018900989,0.03549124,0.7343851],"study_design_scores_gemma":[0.00707057,0.02644415,0.46287623,0.0020762847,0.001162042,0.23762411,0.00064135843,0.0082640285,0.024150355,0.0028038176,0.22677323,0.00011381491],"about_ca_topic_score_codex":0.00022587784,"about_ca_topic_score_gemma":0.00078741414,"teacher_disagreement_score":0.00076391303,"about_ca_system_score_codex":0.00015233907,"about_ca_system_score_gemma":0.00022779795,"threshold_uncertainty_score":0.0025555491},"labels":[],"label_agreement":null},{"id":"W2191286751","doi":"10.2217/ijh.15.22","title":"Update on Recurrent Genetic Aberrations in Acute Myeloid Leukemia","year":2015,"lang":"en","type":"article","venue":"International Journal of Hematologic Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Myeloid leukemia; Medicine; Karyotype; Risk stratification; Oncology; Internal medicine; Bioinformatics; Gene; Chromosome; Genetics; Biology","score_opus":0.04949742693997719,"score_gpt":0.39014997771168153,"score_spread":0.3406525507717043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2191286751","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005370506,0.9864611,0.00059419137,0.004681205,0.005228266,0.000013359467,0.00015872486,0.000052686057,0.0022733435],"genre_scores_gemma":[0.0021463844,0.98098904,0.0012005528,0.0042849123,0.009218711,0.000018360759,0.0003853814,0.000014961424,0.001741709],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99948704,0.00010718572,0.00012215094,0.00006698498,0.00017893572,0.00003770594],"domain_scores_gemma":[0.99701667,0.0014319079,0.00030844493,0.00006597725,0.0009391008,0.00023800138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013824847,0.000639746,0.0014156827,0.0029330004,0.00030369812,0.0011481565,0.0009140862,0.0012451255,0.0034233576],"category_scores_gemma":[0.0034544282,0.0002960604,0.00067516975,0.0025290067,0.00042534963,0.0017389678,0.00073329994,0.002361218,0.0017169334],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013065513,0.000052826406,0.0010530979,0.0072523397,0.00015420547,0.0008959249,0.00009663534,0.00029979702,0.0014144666,0.0013876865,0.21707013,0.7701923],"study_design_scores_gemma":[0.000015123877,0.00008751997,0.0017696642,0.0034852058,0.0002608808,0.0031593065,0.000059933835,0.000093535404,0.00031040926,0.00072621304,0.9900097,0.000022391921],"about_ca_topic_score_codex":0.001275568,"about_ca_topic_score_gemma":0.003449815,"teacher_disagreement_score":0.0034233576,"about_ca_system_score_codex":0.0007098226,"about_ca_system_score_gemma":0.0011203586,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W2576428875","doi":"10.2217/ijh-2016-0014","title":"Management of Multiple Myeloma: The Impact of Ixazomib’s Approval in Canada","year":2016,"lang":"en","type":"article","venue":"International Journal of Hematologic Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; University of Kentucky; International Myeloma Foundation","keywords":"Medicine; Family medicine; Internship; Internal medicine; Medical education","score_opus":0.02964974679434092,"score_gpt":0.3644268375009572,"score_spread":0.3347770907066163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576428875","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058206294,0.15438876,0.000966115,0.66910505,0.007887138,0.00022395981,0.002392199,0.000109938344,0.106720604],"genre_scores_gemma":[0.61360663,0.18259797,0.0050629834,0.16059542,0.00639579,0.0001789547,0.0039335513,0.00040106263,0.027227659],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99246573,0.0009495571,0.00056972314,0.00056183635,0.0038713638,0.0015817994],"domain_scores_gemma":[0.952502,0.005269036,0.0036190734,0.0006336912,0.02102397,0.016952237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005535044,0.00031644022,0.00077136885,0.0015056833,0.0029425498,0.0056785303,0.002255216,0.0032227933,0.010182414],"category_scores_gemma":[0.023121558,0.00036606798,0.0008559456,0.0034536333,0.0021829521,0.0017777847,0.0016314533,0.0046499604,0.0005820922],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024307258,0.00037815573,0.07748932,0.0015806933,0.000358381,0.0032389362,0.00096703734,0.0023570608,0.0012985644,0.03033864,0.36797088,0.5115916],"study_design_scores_gemma":[0.0011757888,0.0005183412,0.16948545,0.0056535937,0.0002848909,0.0023942415,0.0017915274,0.0015465184,0.0005215979,0.0031911016,0.81327754,0.00015937358],"about_ca_topic_score_codex":0.8649526,"about_ca_topic_score_gemma":0.9323918,"teacher_disagreement_score":0.13504738,"about_ca_system_score_codex":0.06123996,"about_ca_system_score_gemma":0.15803145,"threshold_uncertainty_score":0.44432908},"labels":[],"label_agreement":null}]}